Arcus biosciences presents updated data for etrumadenant in third-line metastatic colorectal cancer and new data on its hif-2Α program at the aacr 2021 annual meeting

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival (pfs) and overall survival (os) data in patients with advanced metastatic colorectal cancer (mcrc) from the arc-3 study at the 2021 american association for cancer research (aacr) annual meeting. arc-3 was a phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study that
RCUS Ratings Summary
RCUS Quant Ranking